US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.16 against a street estimate of -0.14 — a miss of 14.3%.
Analysts rate Evolus Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $15.00.
| Fund | Stake |
|---|---|
| Nantahala Capital Management, LLC | 16.96% |
| BlackRock Inc | 7.33% |
| BRAIDWELL LP | 4.78% |
| Frazier Life Sciences Management, L.P. | 3.98% |
| Perceptive Advisors LLC | 3.72% |
| Vanguard Capital Management, LLC | 3.58% |
| Assenagon Asset Management SA | 2.75% |
| Millennium Management LLC | 2.71% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Evolus Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.